Shares of Bicycle Therapeutics plc (NASDAQ: BCYC) hit a new 52-week high at midday on Friday following a stronger-than-expected earnings report. The stock traded as high as $ 60.55 and last traded at $ 59.82, with 2165 shares traded in volume. The stock had previously closed at $ 56.97. The company reported ($ 0.59) earnings per share (EPS) for the quarter, beating analyst consensus estimates of ($ 0.61) by $ 0.02. Bicycle Therapeutics recorded a negative net margin of 546.62% and a negative return on equity of 50.43%.

A number of brokerage firms have recently published reports on BCYC. Piper Sandler raised her price target on Bicycle Therapeutics shares from $ 46.00 to $ 76.00 and assigned the company an “overweight” rating in a report released on Friday, October 8. B. Riley increased his price target on Bicycle Therapeutics stock from $ 56.00 to $ 72.00 and gave the stock a “buy” rating in a report released on Friday, October 8. Zacks Investment Research reduced shares of Bicycle Therapeutics from a buy note to a sell note in a report released on Tuesday, October 12. Canaccord Genuity raised its price target on Bicycle Therapeutics shares from $ 40.00 to $ 60.00 and assigned a “buy” rating to the stock in a report released on Monday, October 11. Finally, Oppenheimer raised its price target on Bicycle Therapeutics shares from $ 47.00 to $ 65 and gave the stock an “outperformance” rating in a report released on Friday, October 8. One analyst rated the stock with a sell rating and eight gave the company’s stock a buy rating. Based on MarketBeat data, Bicycle Therapeutics currently has a consensus rating of “Buy” and an average price target of $ 67.22.

Meanwhile, CFO Lee Kalowski sold 7,500 shares of the company in a transaction that took place on Monday, August 23. The shares were sold for an average price of $ 33.02, for a total value of $ 247,650.00. Following the sale, the CFO now owns 7,500 shares of the company, valued at $ 247,650. The transaction was disclosed in a legal file with the SEC, which can be accessed through the SEC’s website. In addition, CEO Kevin Lee sold 1,808 shares of the company in a transaction that took place on Friday, August 27. The shares were sold at an average price of $ 36.02, for a total trade of $ 65,124.16. Following the completion of the sale, the CEO now directly owns 246,893 shares of the company, valued at approximately $ 8,893,085.86. Disclosure of this sale can be found here. In the past ninety days, insiders have sold 38,163 shares of the company valued at $ 1,550,221. Insiders own 17.90% of the shares of the company.

Several hedge funds and other institutional investors have recently bought and sold shares of BCYC. JPMorgan Chase & Co. purchased a new stake in Bicycle Therapeutics shares in the first quarter valued at approximately $ 39,000. Barclays PLC purchased a new stake in Bicycle Therapeutics during the 1st quarter for a value of approximately $ 612,000. Janus Henderson Group PLC purchased a new stake in Bicycle Therapeutics during the 1st quarter for a value of approximately $ 50,654,000. Schonfeld Strategic Advisors LLC purchased a new stake in Bicycle Therapeutics during the 1st quarter for a value of approximately $ 331,000. Finally, Glenmede Trust Co. NA acquired a new stake in Bicycle Therapeutics during the 1st quarter for a value of approximately $ 295,000. 56.76% of the shares are currently held by institutional investors.

The stock’s fifty-day moving average is $ 46.88 and its two-hundred-day moving average is $ 36.41. The company has a current ratio of 9.36, a quick ratio of 9.36 and a debt ratio of 0.21. The company has a market cap of $ 1.67 billion, a P / E ratio of -20.20 and a beta of -0.29.

Bicycle Therapeutics Company Profile (NASDAQ: BCYC)

Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company engaged in the development of a new class of drugs, which the company calls bicycles, for diseases underserved by existing therapies. The company uses its new proprietary phage display screening platform to identify bicycles.

Recommended story: Special Purpose Acquisition Company (SPAC)

This instant news alert was powered by storytelling technology and MarketBeat financial data to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $ 1,000 in Bicycle Therapeutics now?

Before you consider Bicycle Therapeutics, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat identified the five stocks that top analysts quietly whisper to their clients to buy now before the larger market takes hold of… and Bicycle Therapeutics was not on the list.

Although Bicycle Therapeutics currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better bets.

See the 5 actions here